Citrate Concentrations in Human Seminal Fluid and Expressed Prostatic Fluid Determined via 1H Nuclear Magnetic Resonance Spectroscopy Outperform Prostate Specific Antigen in Prostate Cancer Detection

Journal of Urology

Volumn 176, Issue 5, 2006, Pages 2274-2279

  Kline, Eric E ^a   Treat, Eric G ^a   Averna, Tiffany A ^a   Davis, Michael S ^a   Smith, Anthony Y ^a   Sillerud, Laurel O ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

biomolecular; nuclear magnetic resonance; prostate; prostate specific antigen; prostatic neoplasms; semen

Indexed keywords

CITRIC ACID; PROSTATE SPECIFIC ANTIGEN; PROTON;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE FLUID; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE ANALYSIS; ROC CURVE; SEMINAL PLASMA; SPERM;

AGED; BODY FLUIDS; CITRIC ACID; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SEMEN;

EID: 33750300129     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.07.054     Document Type: Article

References (20)

1. Costello L.C., Littleton G., and Franklin R.B. Regulation of citrate related metabolism in normal and neoplastic prostate. In: Sharma R.K., and Criss W.E. (Eds). Endocrine Control in Neoplasia (1978), Raven Press, New York 303
2. Cooper J.E., and Farid I. The role of citric acid in the physiology of the prostate. A chromatographic study of citric acid cycle intermediates in benign and malignant prostatic tissue. J Surg Res 3 (1963) 112
3. Marberger H., Marberger E., Mann T., and Lutwak-Mann C. Citric acid in human prostatic secretion and metastasizing cancer of prostate gland. Br Med J 1 (1962) 835
4. Costello L.C., Franklin R.B., and Narayan P. Citrate in the diagnosis of prostate cancer. Prostate 38 (1999) 237
5. Sillerud L.O., Halliday K.R., and Griffey R.H. In vivo 13C NMR spectroscopy of the human prostate. Magn Reson Med 8 (1988) 224
6. Halliday K.R., Fenoglio-Preiser C., and Sillerud L.O. Differentiation of human tumors from non-malignant tissue by natural abundance 13C NMR spectroscopy. Magn Reson Med 7 (1988) 384
7. Halliday K.R., Fenoglio-Preiser C., and Sillerud L.O. Carbon-13 and proton nuclear magnetic resonance spectroscopy and microscopy of neoplasms. Adv Pathol 2 (1989) 213
8. Kurhanewicz J., Vigneron D.B., Hricak H., Narayan P., Carrol P., and Nelson S.J. Three dimensional hydrogen-1 MR spectroscopic imaging of the in situ human prostate with high spatial resolution. Radiology 198 (1996) 795
9. Averna T.A., Kline E.E., Smith A.Y., and Sillerud L.O. A decrease in 1H nuclear magnetic resonance spectroscopically determined citrate in human seminal fluid accompanies the development of prostate adenocarcinoma. J Urol 173 (2005) 433
10. Ries, L. A. G., Eisner, M. P., Kosary, C. L., Hankey, B. F., Miller, B. A., Clegg, L. et al: SEER Cancer Statistics Review, 1975-2002. National Cancer Institute, Bethesda, Maryland. Available at http://seer.cancer.gov/csr/1975_2002/. Accessed July 18, 2006
11. Hanley J.A., and McNeil B.J. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148 (1983) 839
12. Lynch M.J., Masters J., Pryor J.P., Lindon J.C., Spraul M., Foxall P.J., et al. Ultra high field NMR spectroscopic studies on human seminal fluid, seminal vesicle and prostatic secretions. J Pharmacol Biomed Anal 12 (1994) 5
13. Mann T., and Lutwak-Mann C. Male Reproductive Function and Semen (1981), Springer-Verlag, Berlin
14. Gjengsto P., Paus E., Halvorsen O.J., Eide J., Akslen L.A., Wentzel-Larsen T., et al. Predictors of prostate cancer evaluated by receiver operating characteristics partial area index: a prospective institutional study. J Urol 173 (2005) 425
15. Nadler R.B., Humphrey P.A., Smith D.S., Catalona W.J., and Ratliff T.L. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 54 (1995) 407
16. Stamey T.A., Caldwell M., McNeal J.E., Nolley R., Hemenez M., and Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?. J Urol 172 (2004) 1297
17. Thompson I.M., Pauler P.K., Goodman P.J., Tangen C.M., Scott Lucia M., Parnes H.L., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med 350 (2004) 2239
18. Shibata A., Ma J., and Whittemore A.S. Prostate cancer incidence and mortality in the United States and the United Kingdom. J Natl Cancer Inst 90 (1998) 1230
19. Thompson I.M., Ankerst D.P., Chi C., Scott Lucia M., Goodman P.J., Crowley J.J., et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. J Am Med Assoc 294 (2005) 66
20. Keetch D.W., Catalona W.J., and Smith D.S. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 151 (1994) 1571